HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Proposed OTC Switch Rule Anticipates Digital World

Executive Summary

FDA’s “Additional Condition for Nonprescription Use” proposal is all about information which won’t be printed on DFLs but will be integral to whether some switch proposals’ approval. But agency doesn’t explicitly exclude switch sponsors from assigning delivery of ACNU information to staff in stores or in online chats.

You may also be interested in...



Could Pharmacist Prescribing Grow In Wake Of Paxlovid Experience?

US FDA’s decision to allow pharmacists to prescribe Pfizer’s COVID-19 antiviral raises hopes and fears that the idea that could be applied more broadly post-pandemic.

IQVIA Consumer Health: Brands Can Beat Inflation, But Only If OTC Firms Raise Their Game

Investments in digitalization, real world evidence and Rx-to-OTC switch can all help OTC companies thrive in a difficult global economic environment, argue IQVIA Consumer Health experts in a recent webinar.

Nicotine Gummies Sold For Smoking Cessation Doused Under US FDA Tobacco Regulations

FDA says warning to VPR Brands could be its first move to reign in sales of nicotine gummies. Statements on brand’s site could indicate sales of nicotine gummies for smoking cessation are on the rise even though the claim isn’t approved.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152681

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel